SYNERGISTIC TUMOR THERAPY WITH COMBINATIONS OF BIOLOGICALLY ACTIVE ANTI-TUMOR ANTIBODIES AND CHEMOTHERAPY

摘要

The invention relates to the use of a therapy combining anticorpale therapy and chemotherapy in the treatment of malignancies. The invention is based in part on the observation of the surprising efficacy of such combined therapies, that several patients receiving L6 antitumor antibody or MG21 had complete remission in response to a subsequent chemotherapeutic treatment, whereas the same patients had responded to similar chemotherapy regimens prior to receiving treatment with L6 antibody or MG21. In embodiments of the present invention, antiglycolipides antibodies, such as preferably the monoclonal antibody or monoclonal antibody L6 MG21, are administered to patients who are then treated with standard chemotherapy regimens. In preferred embodiments of the present invention, chemotherapy is given after several months of treatment anticorpal. It is assumed that the effectiveness of this combination therapy can be attributed to antibodies acting on the tumor site that render the malignant cells more sensitive to the toxic effects of chemotherapeutic agents.